{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:40:45Z","timestamp":1788316845066,"version":"build-2803163510"},"reference-count":98,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>This review aims to synthesize current evidence on the expanding role of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) beyond glycemic control, particularly in the context of critical illness. With growing recognition of their anti-inflammatory, immunomodulatory, and organ-protective properties, GLP-1RAs show promise in managing complications such as sepsis, acute respiratory distress syndrome (ARDS), acute kidney injury, and multiorgan dysfunction. This review explores their mechanisms across vital systems \u2013 including cardiovascular, pulmonary, renal, hepatic, neuropsychiatric, and gut-lung-microbiome axes \u2013 highlighting preclinical and clinical data. By consolidating emerging findings, this review aims to inform future translational research and support the integration of GLP-1RAs into critical care strategies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Recent evidence highlights GLP-1RAs as promising adjuncts in critical illness due to their multiorgan protective effects. In cardiovascular systems, GLP-1RAs improve endothelial function, reduce ischemia-reperfusion injury, and modulate autonomic tone. In the CNS, they provide neuroprotection by reducing neuroinflammation and pyroptosis. In the lungs, they attenuate ARDS by decreasing cytokine production, enhancing surfactant secretion, and restoring alveolar-capillary integrity. Renally, they reduce acute injury and preserve filtration function. In the gut, GLP-1RAs modulate the microbiome, enhance barrier integrity, and lower systemic inflammation via the gut-lung axis. Additionally, they reduce hepatic inflammation and support pancreatic beta-cell survival, improving insulin sensitivity and metabolic stability in critical care.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>GLP-1 receptor agonists hold promise as multiorgan protective agents in critical illness, offering benefits beyond glucose control. Their anti-inflammatory, metabolic, and vaso-protective properties may be harnessed to prevent or attenuate organ failure, support recovery, and improve long-term outcomes in critically ill patients. Further clinical trials are warranted to define their safety, efficacy, and optimal application across ICU populations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mcc.0000000000001294","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T13:00:10Z","timestamp":1749819610000},"page":"370-378","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Exploring the role of glucagon-like peptide-1 receptor agonists in critical illness: mechanisms, benefits, and clinical implications"],"prefix":"10.1097","volume":"31","author":[{"given":"Vidit G.","family":"Jogani","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes, Metabolism, and Nutrition"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman","family":"Mohamed Elfadil","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, Metabolism, and Nutrition"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jithinraj","family":"Edakkanambeth Varayil","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manpreet S.","family":"Mundi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, Metabolism, and Nutrition"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"R1-20250819","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3389\/fendo.2019.00260","article-title":"From the incretin concept and the discovery of GLP-1 to today's diabetes therapy","volume":"10","author":"Holst","year":"2019","journal-title":"Front Endocrinol"},{"key":"R2-20250819","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol"},{"key":"R3-20250819","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1161\/CIR.0000000000001256","article-title":"Forecasting the burden of cardiovascular disease and stroke in the United States through 2050 \u2013 prevalence of risk factors and disease: a presidential advisory from the American Heart Association","volume":"150","author":"Joynt Maddox","year":"2024","journal-title":"Circulation"},{"key":"R4-20250819","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","article-title":"Global, regional, and national prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021","volume":"405","year":"2025","journal-title":"Lancet"},{"key":"R5-20250819","doi-asserted-by":"crossref","first-page":"7770","DOI":"10.3390\/ijms25147770","article-title":"From molecular mechanisms to clinical therapy: understanding sepsis-induced multiple organ dysfunction","volume":"25","author":"Srdi\u0107","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R6-20250819","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2174\/0113816128279655231228055842","article-title":"Free radicals, mitochondrial dysfunction and sepsis-induced organ dysfunction: a mechanistic insight","volume":"30","author":"Kumar","year":"2024","journal-title":"Curr Pharm Des"},{"key":"R7-20250819","doi-asserted-by":"crossref","first-page":"e14229","DOI":"10.1111\/eci.14229","article-title":"Oxidative stress, defective proteostasis and immunometabolic complications in critically ill patients","volume":"54","author":"Galli","year":"2024","journal-title":"Eur J Clin Invest"},{"key":"R8-20250819","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2147\/COPD.S491687","article-title":"Metabolic regulation in acute respiratory distress syndrome: implications for inflammation and oxidative stress","volume":"20","author":"Yue","year":"2025","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"R9-20250819","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cmet.2023.11.009","article-title":"Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation","volume":"36","author":"Wong","year":"2024","journal-title":"Cell Metab"},{"key":"R10-20250819","doi-asserted-by":"crossref","first-page":"18522","DOI":"10.1038\/s41598-021-97967-0","article-title":"Effect of liraglutide on expression of inflammatory genes in type 2 diabetes","volume":"11","author":"Zobel","year":"2021","journal-title":"Sci Rep"},{"key":"R11-20250819","doi-asserted-by":"crossref","first-page":"106320","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol Res"},{"key":"R12-20250819","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/dom.14399","article-title":"Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: a systematic review and meta-analysis of randomised controlled trials","volume":"23","author":"Bray","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"R13-20250819","doi-asserted-by":"crossref","first-page":"1148209","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multifaceted anti-inflammatory agent","volume":"14","author":"Mehdi","year":"2023","journal-title":"Front Immunol"},{"key":"R14-20250819","doi-asserted-by":"crossref","first-page":"706908","DOI":"10.3389\/fphar.2021.706908","article-title":"GLP-1 receptor: a new target for sepsis","volume":"12","author":"Yang","year":"2021","journal-title":"Front Pharmacol"},{"key":"R15-20250819","first-page":"632","article-title":"Relationship between inflammation and metabolic regulation of energy expenditure by GLP-1 in critically ill children","volume":"40","author":"Zaher","year":"2021","journal-title":"Clin Nutr Edinb Scotl"},{"key":"R16-20250819","doi-asserted-by":"crossref","first-page":"114390","DOI":"10.1016\/j.intimp.2025.114390","article-title":"GLP-1 as a regulator of sepsis outcomes: insights into cellular metabolism, inflammation, and therapeutic potential","volume":"152","author":"Fan","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"R17-20250819","doi-asserted-by":"crossref","first-page":"793588","DOI":"10.3389\/fimmu.2021.793588","article-title":"Glucagon-like peptide-1 is associated with systemic inflammation in pediatric patients treated with hematopoietic stem cell transplantation","volume":"12","author":"Ebbesen","year":"2021","journal-title":"Front Immunol"},{"key":"R18-20250819","doi-asserted-by":"crossref","first-page":"e0203223","DOI":"10.1128\/mbio.02032-23","article-title":"Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases","volume":"15","author":"Zeng","year":"2024","journal-title":"mBio"},{"key":"R19-20250819","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000356211","article-title":"Short-chain fatty acid receptor and its contribution to glucagon-like peptide-1 release","volume":"89","author":"Kaji","year":"2014","journal-title":"Digestion"},{"key":"R20-20250819","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/imm.13784","article-title":"GLP-1 receptor agonists alleviate colonic inflammation by modulating intestinal microbiota and the function of group 3 innate lymphoid cells","volume":"172","author":"Sun","year":"2024","journal-title":"Immunology"},{"key":"R21-20250819","doi-asserted-by":"crossref","first-page":"814770","DOI":"10.3389\/fendo.2021.814770","article-title":"Gut microbial signatures for glycemic responses of GLP-1 receptor agonists in type 2 diabetic patients: a pilot study","volume":"12","author":"Tsai","year":"2021","journal-title":"Front Endocrinol"},{"key":"R22-20250819","doi-asserted-by":"crossref","first-page":"175730","DOI":"10.1016\/j.ejphar.2023.175730","article-title":"Dulaglutide provides protection against sepsis-induced lung injury in mice by inhibiting inflammation and apoptosis","volume":"949","author":"Wang","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"R23-20250819","doi-asserted-by":"crossref","first-page":"L368","DOI":"10.1152\/ajplung.00041.2023","article-title":"Liraglutide pretreatment attenuates sepsis-induced acute lung injury","volume":"325","author":"Baer","year":"2023","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"R24-20250819","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/SHK.0000000000002285","article-title":"Liraglutide alleviates acute lung injury and mortality in pneumonia-induced sepsis through regulating surfactant protein expression and secretion","volume":"61","author":"Guo","year":"2024","journal-title":"Shock"},{"key":"R25-20250819","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/08923973.2024.2384897","article-title":"Liraglutide alleviates sepsis-induced acute lung injury by regulating pulmonary surfactant through inhibiting autophagy","volume":"46","author":"Guo","year":"2024","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"R26-20250819","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s12020-024-04033-6","article-title":"The possible effect of antidiabetic agents GLP-1RA and SGLT-2i on the respiratory system function","volume":"87","author":"Kantreva","year":"2025","journal-title":"Endocrine"},{"key":"R27-20250819","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/COPD.S393323","article-title":"The role of glucagon-like peptide-1 receptor agonists in chronic obstructive pulmonary disease","volume":"18","author":"Wang","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"R28-20250819","doi-asserted-by":"crossref","first-page":"1330087","DOI":"10.3389\/fcimb.2023.1330087","article-title":"Dynamic changes in the migratory microbial components of colon tissue during different periods of sepsis in an LPS-induced rat model","volume":"13","author":"Xu","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"R29-20250819","doi-asserted-by":"crossref","first-page":"11602","DOI":"10.3390\/ijms231911602","article-title":"Acute endotoxemia-induced respiratory and intestinal dysbiosis","volume":"23","author":"Goossens","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R30-20250819","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3390\/ijms23031272","article-title":"Salmonella infection causes hyperglycemia for decreased GLP-1 content by enteroendocrine L cells pyroptosis in pigs","volume":"23","author":"Zong","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R31-20250819","doi-asserted-by":"crossref","first-page":"e0199023","DOI":"10.1128\/spectrum.01990-23","article-title":"Gut microbial dysbiosis occurring during pulmonary fungal infection in rats is linked to inflammation and depends on healthy microbiota composition","volume":"11","author":"Popovic","year":"2023","journal-title":"Microbiol Spectr"},{"key":"R32-20250819","doi-asserted-by":"crossref","first-page":"1435180","DOI":"10.3389\/fimmu.2024.1435180","article-title":"Signals from intestinal microbiota mediate the crosstalk between the lung-gut axis in an influenza infection mouse model","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"R33-20250819","doi-asserted-by":"crossref","first-page":"779620","DOI":"10.3389\/fmicb.2021.779620","article-title":"Gut-lung crosstalk in sepsis-induced acute lung injury","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Microbiol"},{"key":"R34-20250819","first-page":"130","article-title":"Gut-lung crosstalk during critical illness","volume":"29","author":"Nath","year":"2023","journal-title":"Curr Opin Crit Care"},{"key":"R35-20250819","doi-asserted-by":"crossref","first-page":"E568","DOI":"10.1152\/ajpendo.00292.2020","article-title":"Glucagon-like peptide-1 receptor mediates the beneficial effect of liraglutide in an acute lung injury mouse model involving the thioredoxin-interacting protein","volume":"319","author":"Zhou","year":"2020","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R36-20250819","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41374-018-0170-0","article-title":"Glucagon-like peptide-1 receptor activation alleviates lipopolysaccharide-induced acute lung injury in mice via maintenance of endothelial barrier function","volume":"99","author":"Xu","year":"2019","journal-title":"Lab Investig J Tech Methods Pathol"},{"key":"R37-20250819","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"R38-20250819","doi-asserted-by":"crossref","first-page":"7917","DOI":"10.3390\/ijms22157917","article-title":"Favorable effects of GLP-1 receptor agonist against pancreatic \u03b2-cell glucose toxicity and the development of arteriosclerosis: \u201cthe earlier, the better\u201d in therapy with incretin-based medicine","volume":"22","author":"Kaneto","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R39-20250819","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"R40-20250819","doi-asserted-by":"crossref","first-page":"1431292","DOI":"10.3389\/fendo.2024.1431292","article-title":"Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists","volume":"15","author":"Liu","year":"2024","journal-title":"Front Endocrinol"},{"key":"R41-20250819","doi-asserted-by":"crossref","first-page":"114817","DOI":"10.1016\/j.bcp.2021.114817","article-title":"Phytochemicals modulate pancreatic islet ( cell function through glucagon-like peptide-1-related mechanisms","volume":"197","author":"Zheng","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"R42-20250819","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/endrev\/bnac018","article-title":"Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease","volume":"44","author":"Yabut","year":"2023","journal-title":"Endocr Rev"},{"key":"R43-20250819","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/bph.15485","article-title":"Metabolic responses and benefits of glucagon-like peptide-1 (GLP-1) receptor ligands","volume":"179","author":"Tanday","year":"2022","journal-title":"Br J Pharmacol"},{"key":"R44-20250819","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41574-022-00783-3","article-title":"Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1","volume":"19","author":"Hammoud","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"R45-20250819","first-page":"6459","article-title":"Oxidative stress and inflammation in COVID-19: potential application OF GLP-1 receptor agonists","volume":"27","author":"Abudalo","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R46-20250819","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s11033-024-09793-y","article-title":"From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists","volume":"51","author":"Dave","year":"2024","journal-title":"Mol Biol Rep"},{"key":"R47-20250819","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","article-title":"American Association of Clinical Endocrinology Clinical Practice Guideline: developing a diabetes mellitus comprehensive care plan\u20142022 update","volume":"28","author":"Blonde","year":"2022","journal-title":"Endocr Pract"},{"key":"R48-20250819","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2147\/DMSO.S387116","article-title":"The efficacy of GLP-1 analogues on appetite parameters, gastric emptying, food preference and taste among adults with obesity: systematic review of randomized controlled trials","volume":"16","author":"Aldawsari","year":"2023","journal-title":"Diabetes Metab Syndr Obes"},{"key":"R49-20250819","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/clinem\/dgae719","article-title":"Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide","volume":"110","author":"Jalleh","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"R50-20250819","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.14309\/ajg.0000000000002519","article-title":"Effects of GLP-1 and other gut hormone receptors on the gastrointestinal tract and implications in clinical practice","volume":"119","author":"Camilleri","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"R51-20250819","doi-asserted-by":"crossref","first-page":"bqae155","DOI":"10.1210\/endocr\/bqae155","article-title":"Physiology and pharmacology of effects of GLP-1-based therapies on gastric, biliary and intestinal motility","volume":"166","author":"Jalleh","year":"2024","journal-title":"Endocrinology"},{"key":"R52-20250819","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2468-1253(24)00188-2","article-title":"Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions","volume":"9","author":"Jalleh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R53-20250819","doi-asserted-by":"crossref","first-page":"G617","DOI":"10.1152\/ajpgi.00175.2021","article-title":"Mechanisms underlying the prokinetic effects of endogenous glucagon-like peptide-1 in the rat proximal colon","volume":"321","author":"Nakamori","year":"2021","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R54-20250819","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/bph.15611","article-title":"Actions of glucagon-like peptide-1 receptor ligands in the gut","volume":"179","author":"Holst","year":"2022","journal-title":"Br J Pharmacol"},{"key":"R55-20250819","doi-asserted-by":"crossref","first-page":"113236","DOI":"10.1016\/j.biopha.2022.113236","article-title":"Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases","volume":"152","author":"Yang","year":"2022","journal-title":"Biomed Pharmacother Biomedecine Pharmacother"},{"key":"R56-20250819","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int"},{"key":"R57-20250819","doi-asserted-by":"crossref","first-page":"e027712","DOI":"10.1161\/JAHA.122.027712","article-title":"GLP-1 promotes cortical and medullary perfusion in the human kidney and maintains renal oxygenation during NaCl loading","volume":"12","author":"Haddock","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"R58-20250819","doi-asserted-by":"crossref","first-page":"738848","DOI":"10.3389\/fendo.2021.738848","article-title":"Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system","volume":"12","author":"Puglisi","year":"2021","journal-title":"Front Endocrinol"},{"key":"R59-20250819","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.3390\/jcm10173955","article-title":"GLP-1 receptor agonists in diabetic kidney disease: from physiology to clinical outcomes","volume":"10","author":"Rojano Toimil","year":"2021","journal-title":"J Clin Med"},{"key":"R60-20250819","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00592-023-02184-y","article-title":"GLP-1RAs inhibit the activation of the NLRP3 inflammasome signaling pathway to regulate mouse renal podocyte pyroptosis","volume":"61","author":"Li","year":"2024","journal-title":"Acta Diabetol"},{"key":"R61-20250819","doi-asserted-by":"crossref","first-page":"111603","DOI":"10.1016\/j.cellsig.2025.111603","article-title":"Effect of the glucagon-like peptide-1 receptor agonists dulaglutide on kidney outcomes in db\/db mice","volume":"127","author":"Deng","year":"2025","journal-title":"Cell Signal"},{"key":"R62-20250819","doi-asserted-by":"crossref","first-page":"1163288","DOI":"10.3389\/fimmu.2023.1163288","article-title":"GLP-1 RAs and SGLT2i: two antidiabetic agents associated with immune and inflammation modulatory properties through the common AMPK pathway","volume":"14","author":"Mazzieri","year":"2023","journal-title":"Front Immunol"},{"key":"R63-20250819","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.cmet.2024.05.001","article-title":"Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule","volume":"36","author":"Ben Nasr","year":"2024","journal-title":"Cell Metab"},{"key":"R64-20250819","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1038\/s41467-024-50199-y","article-title":"GLP-1 receptor agonists\u2019 impact on cardio-renal outcomes and mortality in T2D with acute kidney disease","volume":"15","author":"Pan","year":"2024","journal-title":"Nat Commun"},{"key":"R65-20250819","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/MNH.0000000000001066","article-title":"Glucagon-like peptide-1 receptor agonists to improve cardiorenal outcomes: data from FLOW and beyond","volume":"34","author":"Faruque","year":"2025","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R66-20250819","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/ckj\/sfac274","article-title":"Tirzepatide and prevention of chronic kidney disease","volume":"16","author":"Bosch","year":"2023","journal-title":"Clin Kidney J"},{"key":"R67-20250819","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.eprac.2023.11.007","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: a systematic review and meta-analysis","volume":"30","author":"Ansari","year":"2024","journal-title":"Endocr Pract"},{"key":"R69-20250819","doi-asserted-by":"crossref","first-page":"e250802","DOI":"10.1001\/jamanetworkopen.2025.0802","article-title":"Hematologic cancers among patients with type 2 diabetes prescribed GLP-1 receptor agonists","volume":"8","author":"Ashruf","year":"2025","journal-title":"JAMA Netw Open"},{"key":"R70-20250819","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential","volume":"17","author":"Ma","year":"2021","journal-title":"Int J Biol Sci"},{"key":"R71-20250819","first-page":"1816","article-title":"Biology and clinical use of glucagon-like peptide-1 receptor agonists in vascular protection","volume":"39","author":"Yau","year":"2023","journal-title":"Can J Cardiol"},{"key":"R72-20250819","doi-asserted-by":"crossref","first-page":"102355","DOI":"10.1016\/j.coph.2023.102355","article-title":"The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: a mini-review of the potential mechanisms","volume":"69","author":"Ribeiro-Silva","year":"2023","journal-title":"Curr Opin Pharmacol"},{"key":"R73-20250819","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10741-024-10450-6","article-title":"GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction","volume":"30","author":"Bonfioli","year":"2025","journal-title":"Heart Fail Rev"},{"key":"R74-20250819","doi-asserted-by":"crossref","first-page":"983961","DOI":"10.3389\/fphys.2022.983961","article-title":"The potential of glucagon-like peptide-1 receptor agonists in heart failure","volume":"13","author":"Kreiner","year":"2022","journal-title":"Front Physiol"},{"key":"R75-20250819","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12933-022-01454-3","article-title":"The gut hormone glucose-dependent insulinotropic polypeptide is downregulated in response to myocardial injury","volume":"21","author":"Kahles","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"R76-20250819","doi-asserted-by":"crossref","first-page":"113517","DOI":"10.1016\/j.biopha.2022.113517","article-title":"Glucose control independent mechanisms involved in the cardiovascular benefits of glucagon-like peptide-1 receptor agonists","volume":"153","author":"Wu","year":"2022","journal-title":"Biomed Pharmacother Biomedecine Pharmacother"},{"key":"R77-20250819","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"key":"R78-20250819","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"R79-20250819","doi-asserted-by":"crossref","first-page":"4900","DOI":"10.3390\/ijms25094900","article-title":"Peptides are cardioprotective drugs of the future: the receptor and signaling mechanisms of the cardioprotective effect of glucagon-like peptide-1 receptor agonists","volume":"25","author":"Boshchenko","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R80-20250819","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.3390\/jcm13164674","article-title":"Cardiovascular protective properties of GLP-1 receptor agonists: more than just diabetic and weight loss drugs","volume":"13","author":"Le","year":"2024","journal-title":"J Clin Med"},{"key":"R81-20250819","doi-asserted-by":"crossref","first-page":"e240046","DOI":"10.1530\/JOE-24-0046","article-title":"GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms","volume":"263","author":"Mullur","year":"2024","journal-title":"J Endocrinol"},{"key":"R82-20250819","doi-asserted-by":"crossref","first-page":"H1159","DOI":"10.1152\/ajpheart.00574.2023","article-title":"GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage","volume":"326","author":"Park","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R83-20250819","doi-asserted-by":"crossref","first-page":"110311","DOI":"10.1016\/j.intimp.2023.110311","article-title":"Tirzepatide attenuates lipopolysaccharide-induced left ventricular remodeling and dysfunction by inhibiting the TLR4\/NF-kB\/NLRP3 pathway","volume":"120","author":"Liu","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"R84-20250819","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bph.15682","article-title":"Glucagon-like peptide-1 (GLP-1) signalling in the brain: from neural circuits and metabolism to therapeutics","volume":"179","author":"Kabahizi","year":"2022","journal-title":"Br J Pharmacol"},{"key":"R85-20250819","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1161\/CIR.0000000000000691","article-title":"Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017\u200aACC\/AHA\/HFSA heart failure guideline update","volume":"140","author":"Dunlay","year":"2019","journal-title":"Circulation"},{"key":"R86-20250819","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/bph.15462","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits\u2014the role of the GLP-1 receptor","volume":"179","author":"Helmst\u00e4dter","year":"2022","journal-title":"Br J Pharmacol"},{"key":"R87-20250819","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10557-022-07360-w","article-title":"Effects of glucagon-like peptide-1 receptor agonist (GLP-1RA) on cardiac structure and function: a systematic review and meta-analysis of randomized-controlled trials","volume":"38","author":"Wong","year":"2024","journal-title":"Cardiovasc Drugs Ther"},{"key":"R88-20250819","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.3390\/molecules28031369","article-title":"Cardiovascular protection with a long-acting GLP-1 receptor agonist liraglutide: an experimental update","volume":"28","author":"Vandemark","year":"2023","journal-title":"Molecules"},{"key":"R89-20250819","doi-asserted-by":"crossref","first-page":"1525623","DOI":"10.3389\/fimmu.2025.1525623","article-title":"The immunomodulatory effects of GLP-1 receptor agonists in neurogenerative diseases and ischemic stroke treatment","volume":"16","author":"Sun","year":"2025","journal-title":"Front Immunol"},{"key":"R90-20250819","doi-asserted-by":"crossref","first-page":"109653","DOI":"10.1016\/j.intimp.2022.109653","article-title":"The GLP-1 receptor agonist exenatide ameliorates neuroinflammation, locomotor activity, and anxiety-like behavior in mice with diet-induced obesity through the modulation of microglial M2 polarization and downregulation of SR-A4","volume":"115","author":"Lin","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"R91-20250819","doi-asserted-by":"crossref","first-page":"106550","DOI":"10.1016\/j.phrs.2022.106550","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment","volume":"186","author":"Kopp","year":"2022","journal-title":"Pharmacol Res"},{"key":"R92-20250819","doi-asserted-by":"crossref","first-page":"970925","DOI":"10.3389\/fnins.2022.970925","article-title":"The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: an in-depth review","volume":"16","author":"Reich","year":"2022","journal-title":"Front Neurosci"},{"key":"R93-20250819","doi-asserted-by":"crossref","first-page":"175439","DOI":"10.1016\/j.ejphar.2022.175439","article-title":"Alternative role of glucagon-like peptide-1 receptor agonists in neurodegenerative diseases","volume":"938","author":"Chen","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"R94-20250819","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12933-022-01686-3","article-title":"Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms","volume":"21","author":"Verg\u00e8s","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"R95-20250819","doi-asserted-by":"crossref","first-page":"844697","DOI":"10.3389\/fneur.2022.844697","article-title":"Neuroprotective mechanisms of glucagon-like peptide-1-based therapies in ischemic stroke: an update based on preclinical research","volume":"13","author":"Yang","year":"2022","journal-title":"Front Neurol"},{"key":"R96-20250819","doi-asserted-by":"crossref","first-page":"176191","DOI":"10.1016\/j.ejphar.2023.176191","article-title":"Intranasal Exendin-4 modifies necroptosis-mediated innate immune response to combat septic encephalopathy in rats: Role of mTORC1 in immunogenic and tolerogenic cell demise","volume":"961","author":"Zaky","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"R97-20250819","doi-asserted-by":"crossref","first-page":"114348","DOI":"10.1016\/j.expneurol.2023.114348","article-title":"Activation of glucagon-like peptide-1 receptor in microglia exerts protective effects against sepsis-induced encephalopathy via attenuating endoplasmic reticulum stress-associated inflammation and apoptosis in a mouse model of sepsis","volume":"363","author":"Yi","year":"2023","journal-title":"Exp Neurol"},{"key":"R98-20250819","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3892\/ijmm.2025.5515","article-title":"Role of GLP-1 receptor agonists in sepsis and their therapeutic potential in sepsis-induced muscle atrophy (review)","volume":"55","author":"Zhao","year":"2025","journal-title":"Int J Mol Med"},{"key":"R99-20250819","doi-asserted-by":"crossref","first-page":"8214","DOI":"10.3390\/ijms25158214","article-title":"Impact of selected glucagon-like peptide-1 receptor agonists on serum lipids, adipose tissue, and muscle metabolism-a narrative review","volume":"25","author":"Szekeres","year":"2024","journal-title":"Int J Mol Sci"}],"container-title":["Current Opinion in Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCC.0000000000001294","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T18:01:40Z","timestamp":1755626500000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCC.0000000000001294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":98,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mcc.0000000000001294","relation":{},"ISSN":["1070-5295","1531-7072"],"issn-type":[{"value":"1070-5295","type":"print"},{"value":"1531-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]}}}